Neurovascular Determinants of Cognitive Function in Adults With Sickle Cell Disease

Sickle Cell Disease Clinical Trial

Official title:

Neurovascular Determinants of Cognitive Function in Adults With Sickle Cell Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02946905
• Other study ID #: 12040139
• Status: Completed
• Start date: April 2016
• Est. completion date: March 31, 2023

Study information

• Verified date: April 2023
• Source: University of Pittsburgh
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Cognitive impairment is a poorly understood, serious, and emerging complication for adult patients with sickle cell disease. Because there is extensive microvascular damage from oxidative damage in sickle cell disease, the investigators hypothesize that this is also present in the cerebral microvasculature to cause cognitive impairment. The investigators plan to test this by correlating markers of inflammation and oxidative damage with cognitive performance and 7 Tesla brain MRI microvascular findings in these patients, with the long term goal of understanding the mechanisms and risk factors of cognitive impairment in sickle cell disease.

Description:

The Neurovascular Determinants of Cognitive Function in Adults with Sickle Cell Disease is a study for adults 18 and older who have been diagnosed with Sickle Cell Disease (SCD). Many adult patients with SCD suffer from cognitive impairment (CI), a serious complication responsible for severe functional limitations, and whose pathogenesis, risk factors, and natural history are unknown. This research project will look at cognitive performance and 7 Tesla brain MRI findings along with markers of inflammation and oxidation to better understand the mechanism and risk factors. The investigators will complete a baseline assessment. SCD participants will be seen for follow-up at 3 and 5 years. Non-SCD participants will be seen for follow-up at 3 years. All assessments are completed at no cost and there is compensation for participation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 226
• Est. completion date: March 31, 2023
• Est. primary completion date: March 31, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age 18 and above

2. Able to provide informed consent

For Non-SCD :

1. Between age 18 and 55

2. Able to provide informed consent

3. Are age, race, and gender matched to a Sickle Cell Disease study subject.

Exclusion Criteria:

1. Age less than 18 years

2. Current pregnancy or lactation

3. Any medical condition that may result in neurocognitive or brain dysfunction that is

not secondary to SCD including:

1. Diabetes mellitus

2. Coronary artery disease

3. Peripheral vascular disease

4. Other causes of cerebral vasculitis such as Systemic Lupus Erythematosus (SLE)

4. Any contraindication to MRI scanning including:

1. History of claustrophobia

2. Presence of metallic implants such as cardiac pacemaker or implantable defibrillator, surgical aneurysm clips, or any implanted device (e.g. insulin pump, drug infusion device)

3. Any known metal fragments embedded in the body (eg: ear implant)

4. Neural stimulator (e.g. Transcutaneous Electrical Nerve Stimulation Unit)

5. Metal in the eye (e.g. from machining)

6. Any metallic foreign body, shrapnel, or bullet

7. Inability to lie still for 30 minutes or more

5. Inability to provide direct consent

6. In a current medical or pain crisis as diagnosed by attending physician -

Related Conditions & MeSH terms

• Anemia, Sickle Cell
• Sickle Cell Disease

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University of Pittsburgh

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	7 Tesla MRI	Multiple conventional and novel markers of small vessel disease will be evaluated.	5 years
Secondary	Inflammation	Blood biomarkers of inflammation will be collected	5 years
Secondary	Oxidative markers	Blood biomarkers of oxidative markers will be collected.	5 years